Location History:
- La Jolla, CA (US) (1993)
- San Diego, CA (US) (1995)
Company Filing History:
1 out of 1,187 
1 out of 832,880 Years Active: 1993-1995
Title: The Innovative Contributions of Jin-Jun Liu
Introduction
Jin-Jun Liu is a notable inventor based in La Jolla, California. He has made significant contributions in the field of synthetic chemistry, particularly in the total synthesis of taxol and its analogs. With a total of two patents to his name, his work stands out in the pharmaceutical sector.
Latest Patents
Liu's latest patents showcase his innovative approaches in the synthesis of taxol. The first patent, titled "Total synthesis of taxol and taxol analogs," employs a convergent synthetic plan that allows for the creation of a wide variety of taxol analogs. These analogs, possessing skeletal extensions, are produced using this novel synthetic strategy, which cannot be achieved through mere modification of the natural product.
His second patent focuses on "Intermediates for preparation of taxols." It describes a specific taxol intermediate comprising various structural components, allowing for the creation of diverse compounds. This technology is crucial for advancing the development of taxol and its analogs, as it opens up possibilities for new therapeutic agents.
Career Highlights
Throughout his career, Jin-Jun Liu has been affiliated with reputable institutions, including The Scripps Research Institute. His expertise in synthesis has led him to focus on developing innovative methodologies that have wide-ranging applications in the pharmaceutical industry.
Collaborations
Liu's work has often involved collaborations with distinguished peers, such as K C Nicolaou and Chan-Kou Hwang. These partnerships have facilitated knowledge exchange and have played a pivotal role in furthering his research endeavors.
Conclusion
Jin-Jun Liu's contributions to the realm of synthetic chemistry, particularly through his patents on taxol synthesis, underscore his role as a key inventor in modern pharmacology. His innovative approaches continue to pave the way for new drug development, ultimately enhancing therapeutic options available to patients worldwide.